The Progression of Inflammation Parallels the Dermal Angiogenesis in a Keratin 14 IL-4-Transgenic Model of Atopic Dermatitis

REFERENCES

• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15–18
   PubMed Web of Science ®Google Scholar
• Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006; 28: 1779–1802
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler W M, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai A A, Rolland F, Demkow T, Hutson T E, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski R M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–134
   PubMed Web of Science ®Google Scholar
• Motzer R J, Michaelson M D, Redman B G, Hudes G R, Wilding G, Figlin R A, Ginsberg M S, Kim S T, Baum C M, De Primo S E, Li J Z, Bello C L, Theuer C P, George D J, Rini B I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• Feldman D R, Motzer R J. Novel targets and therapies for metastatic renal cell carcinoma. Oncology (Williston Park) 2006; 20: 1745–1753, discussion 1756
   Google Scholar
• Bagli E, Xagorari A, Papetropoulos A, Murphy C, Fotsis T. Angiogenesis in inflammation. Autoimmun Rev 2004; 3: S26, (Suppl 1)
   Google Scholar
• Brennen W N, Cooper C R, Capitosti S, Brown M L, Sikes R A. Thalidomide and analogues: current proposed mechanisms and therapeutic usage. Clin Prostate Cancer 2004; 3: 54–61
   PubMedGoogle Scholar
• Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int 2004; 54: 285–294
   PubMed Web of Science ®Google Scholar
• Gately S, Li W W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004; 31: 2–11
   PubMed Web of Science ®Google Scholar
• Koehne C H, Dubois R N. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12–21
   PubMed Web of Science ®Google Scholar
• Streck C J, Zhang Y, Miyamoto R, Zhou J, Ng C Y, Nathwani A C, Davidoff A M. Restriction of neuroblastoma angiogenesis and growth by interferon-alpha/beta. Surgery 2004; 136: 183–189
   Google Scholar
• Shishodia S, Aggarwal B B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 2004; 64: 5004–5012
   PubMed Web of Science ®Google Scholar
• Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe D D, Shalinsky D R, Thurston G, Yancopoulos G D, McDonald D M. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35–52
   PubMed Web of Science ®Google Scholar
• Grosios K, Wood J, Esser R, Raychaudhuri A, Dawson J. Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm Res 2004; 53: 133–142
   PubMed Web of Science ®Google Scholar
• Leung D Y, Bieber T. Atopic dermatitis. Lancet 2003; 361: 151–160
   PubMed Web of Science ®Google Scholar
• Leung D Y, Boguniewicz M, Howell M D, Nomura I, Hamid Q A. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651–657
   PubMed Web of Science ®Google Scholar
• Agha-Majzoub R, Becker R P, Schraufnagel D E, Chan L S. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation 2005; 12: 455–476
   Web of Science ®Google Scholar
• Chan L S, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001; 117: 977–983
   PubMed Web of Science ®Google Scholar
• Chen L, Martinez O, Venkataramani P, Lin S X, Prabhakar B S, Chan L S. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 2005; 139: 189–201
   Google Scholar
• Chen L, Lin S X, Overbergh L, Mathieu C, Chan L S. The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the upregulations of B cell activation molecules, proliferation, and surface and serum IgE. Clin Exp Immunol 2005; 142: 21–30
   PubMedGoogle Scholar
• Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar B S, Chan L S. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 2004; 138: 375–387
   PubMed Web of Science ®Google Scholar
• Zhang Y, Matsuo H, Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 2006; 297: 425–429
   Google Scholar
• Shih S C, Robinson G S, Perruzzi C A, Calvo A, Desai K, Green J E, Ali I U, Smith L E, Senger D R. Molecular profiling of angiogenesis markers. Am J Pathol 2002; 161: 35–41
   PubMed Web of Science ®Google Scholar
• Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen H R. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Endocrinology 2005; 146: 4545–4554
   PubMed Web of Science ®Google Scholar
• Shih S C, Ju M, Liu N, Smith L E. Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 2003; 112: 50–57
   PubMed Web of Science ®Google Scholar
• Thijssen V L, Brandwijk R J, Dings R P, Griffioen A W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004; 299: 286–293
   Google Scholar
• Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25: 386–401
   PubMed Web of Science ®Google Scholar
• Hulthen U L, Cao Z, Rumble J R, Cooper M E, Johnston C I. Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade. Am J Hypertens 1996; 9: 895–901
   Google Scholar
• Ruhrberg C. Growing and shaping the vascular tree: multiple roles for VEGF. Bioessays 2003; 25: 1052–1060
   PubMed Web of Science ®Google Scholar
• Yancopoulos G D, Davis S, Gale N W, Rudge J S, Wiegand S J, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439
   PubMed Web of Science ®Google Scholar
• Lee S S, Joo Y S, Kim W U, Min D J, Min J K, Park S H, Cho C S, Kim H Y. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001; 19: 321–324
   PubMed Web of Science ®Google Scholar
• Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998; 27: 377–380
   PubMed Web of Science ®Google Scholar
• Detmar M, Yeo K T, Nagy J A, Van de Water L, Brown L F, Berse B, Elicker B M, Ledbetter S, Dvorak H F. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol 1995; 105: 44–50
   PubMed Web of Science ®Google Scholar
• Trompezinski S, Denis A, Vinche A, Schmitt D, Viac J. IL-4 and interferon-gamma differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts. Exp Dermatol 2002; 11: 224–231
   Google Scholar
• Chen L, Lin S X, Agha-Majzoub R, Overbergh L, Mathieu C, Chan L S. CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14-IL-4-transgenic mouse model. Int Immunol 2006; 18: 1233–1242
   PubMedGoogle Scholar
• Maisonpierre P C, Suri C, Jones P F, Bartunkova S, Wiegand S J, Radziejewski C, Compton D, McClain J, Aldrich T H, Papadopoulos N, Daly T J, Davis S, Sato T N, Yancopoulos G D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55–60
   PubMed Web of Science ®Google Scholar
• Guenzi E, Topolt K, Cornali E, Lubeseder-Martellato C, Jorg A, Matzen K, Zietz C, Kremmer E, Nappi F, Schwemmle M, Hohenadl C, Barillari G, Tschachler E, Monini P, Ensoli B, Sturzl M. The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. Embo J 2001; 20: 5568–5577
   PubMedGoogle Scholar
• Guenzi E, Topolt K, Lubeseder-Martellato C, Jorg A, Naschberger E, Benelli R, Albini A, Sturzl M. The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J 2003; 22: 3772–3782
   PubMedGoogle Scholar
• Bhushan M, Young H S, Brenchley P E, Griffiths C E. Recent advances in cutaneous angiogenesis. Br J Dermatol 2002; 147: 418–425
   Google Scholar
• Reinders M E, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss K E, Geehan C S, Luster A D, Sayegh M H, Briscoe D M. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003; 112: 1655–1665
   PubMed Web of Science ®Google Scholar
• Xia Y P, Li B, Hylton D, Detmar M, Yancopoulos G D, Rudge J S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102: 161–168
   PubMed Web of Science ®Google Scholar
• Nakamura M, Abe Y, Tokunaga T. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int 2002; 52: 331–339
   PubMed Web of Science ®Google Scholar
• Frank S, Hubner G, Breier G, Longaker M T, Greenhalgh D G, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes: implications for normal and impaired wound healing. J Biol Chem 1995; 270: 12607–12613
   PubMed Web of Science ®Google Scholar
• Ancelin M, Chollet-Martin S, Herve M A, Legrand C, El Benna J, Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest 2004; 84: 502–512
   PubMed Web of Science ®Google Scholar
• Mor F, Quintana F J, Cohen I R. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004; 172: 4618–4623
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown L F, Schon M P, Elicker B M, Velasco P, Richard L, Fukumura D, Monsky W, Claffey K P, Jain R K. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998; 111: 1–6
   PubMed Web of Science ®Google Scholar
• Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029–1039
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand S J, Yancopoulos G D. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356–5362
   PubMed Web of Science ®Google Scholar
• Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos G D, Isner J M. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83: 233–240
   PubMed Web of Science ®Google Scholar
• Papapetropoulos A, Garcia-Cardena G, Dengler T J, Maisonpierre P C, Yancopoulos G D, Sessa W C. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213–223
   PubMed Web of Science ®Google Scholar
• Sato T N, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70–74
   PubMed Web of Science ®Google Scholar
• Teichert-Kuliszewska K, Maisonpierre P C, Jones N, Campbell A I, Master Z, Bendeck M P, Alitalo K, Dumont D J, Yancopoulos G D, Stewart D J. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001; 49: 659–670
   PubMed Web of Science ®Google Scholar
• Kim I, Kim J H, Moon S O, Kwak H J, Kim N G, Koh G Y. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Oncogene 2000; 19: 4549–4552
   PubMed Web of Science ®Google Scholar
• Gale N W, Thurston G, Hackett S F, Renard R, Wang Q, McClain J, Martin C, Witte C, Witte M H, Jackson D, Suri C, Campochiaro P A, Wiegand S J, Yancopoulos G D. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002; 3: 411–423
   PubMed Web of Science ®Google Scholar
• Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48–50
   PubMed Web of Science ®Google Scholar
• Thurston G. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat 2002; 200: 575–580
   PubMed Web of Science ®Google Scholar
• Bach T L, Barsigian C, Chalupowicz D G, Busler D, Yaen C H, Grant D S, Martinez J. VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 1998; 238: 324–334
   PubMed Web of Science ®Google Scholar
• Gory-Faure S, Prandini M H, Pointu H, Roullot V, Pignot-Paintrand I, Vernet M, Huber P. Role of vascular endothelial-cadherin in vascular morphogenesis. Development 1999; 126: 2093–2102
   PubMed Web of Science ®Google Scholar
• Zanetti A, Lampugnani M G, Balconi G, Breviario F, Corada M, Lanfrancone L, Dejana E. Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling. Arterioscler Thromb Vasc Biol 2002; 22: 617–622
   Google Scholar
• Esser S, Lampugnani M G, Corada M, Dejana E, Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998; 111: 1853–1865, (Pt 13)
   PubMed Web of Science ®Google Scholar
• Naschberger E, Bauer M, Sturzl M. Human guanylate binding protein-1 (hGBP-1) characterizes and establishes a non-angiogenic endothelial cell activation phenotype in inflammatory diseases. Adv Enzyme Regul 2005; 45: 215–227
   PubMedGoogle Scholar
• Lubeseder-Martellato C, Guenzi E, Jorg A, Topolt K, Naschberger E, Kremmer E, Zietz C, Tschachler E, Hutzler P, Schwemmle M, Matzen K, Grimm T, Ensoli B, Sturzl M. Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am J Pathol 2002; 161: 1749–1759
   PubMedGoogle Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364
   PubMed Web of Science ®Google Scholar